Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Submission of Matters to a Vote of Security Holders

ITEM 5.07 Submission of Matters to a Vote of Security Holders

Endocyte, Inc. (the Company) held its 2017 annual meeting of
stockholders on May 4, 2017. The Companys stockholders took the
following actions on the business items which were set forth in
the notice for the meeting:

Proposal 1 Election of Directors: elected four (4) directors for
three-year terms ending at the 2020 annual meeting of
stockholders;

Proposal 2 Ratification of Independent Registered Public
Accounting Firm: ratified the Audit Committees appointment of
Ernst Young LLP as the Companys independent registered public
accounting firm for 2017.

Proposal 3 Advisory Vote on Executive Compensation (Say-on-Pay):
approved the compensation of the Named Executive Officers.

Proposal 4 Advisory Vote on Frequency of Future Advisory
Say-on-Pay Votes: submitted, on an advisory basis, a majority of
votes for the holding of future advisory Say-on-Pay votes on
executive compensation every year.

The vote tabulation for each proposal is as follows:

Proposal 1 Election of Directors

Proposal 2 Ratification of Independent Registered Public
Accounting Firm

Proposal 3 Advisory Vote on Executive Compensation

Proposal 4 Advisory Vote on Frequency of Future Advisory
Say-on-Pay Votes

Based on the advisory vote results on the frequency of future
Say-on-Pay votes, and consistent with the recommendation of the
Companys Board of Directors (the Board), the Board has determined
that the Company will hold a shareholder advisory Say-on-Pay vote
every year until the next required vote on the frequency of
future Say-on-Pay votes.

About Endocyte, Inc.  (NASDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Endocyte, Inc.  (NASDAQ:ECYT) Recent Trading Information

Endocyte, Inc.  (NASDAQ:ECYT) closed its last trading session 00.00 at 2.27 with 349,095 shares trading hands.